Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Salestools Logo

Salestools

L'agent IA #1 pour les équipes de vente et Go-to-Market. Vendez plus, plus vite, avec moins d'effort.

Produit

  • Agents de vente IA
  • Données d'intention
  • Données technologiques
  • Suivi des visiteurs
  • Copilote
  • Vente sociale

Solutions

  • Service client
  • E-commerce
  • SaaS
  • Entreprise
  • Petite entreprise

Ressources

  • Le rapport
  • Documentation
  • Référence API
  • Centre d'aide
  • Blog
  • Études de cas
  • Webinaires

Entreprise

  • À propos
  • Carrières
  • Presse
  • Contact
  • Partenaires

Nos bureaux

  • New York, HQ
  • Bucarest, Laboratoire de recherche IA
  • Zug, Suisse

© 2026 Salestools. Tous droits réservés.

Conditions relatives aux données et sécuritéPolitique de confidentialitéConditions de serviceAcceptable Use
Tous les systèmes opérationnels
Salestools LogoSalestools
Agents IA Salestools
Solutions
Ressources
Entreprise
Tarifs
Back to Reports
Biotech

VectorIntelligence

VectorIntelligence Raises $400M Series D to Transform Biotech

Seattle, WAOctober 4, 20251 min read
Total Raised
$400M Series D
Valuation
$5B
Latest Round
Series
Employees
250-500

VectorIntelligence Raises $400M Series D in Latest Funding Round

VectorIntelligence has successfully closed a $400M Series D funding round, marking a significant milestone in the company's growth trajectory. The round was led by Andreessen Horowitz, with participation from NEA.

Company Overview

Founded in 2020 and headquartered in Seattle, WA, VectorIntelligence has established itself in the Biotech space. Leading machine learning platform automating enterprise workflows with advanced AI models

With a current valuation of $5B, the company has demonstrated strong market traction and investor confidence.

Investment Details

  • Amount Raised: $400M Series D
  • Valuation: $5B
  • Lead Investor: Andreessen Horowitz

Future Outlook

As VectorIntelligence moves forward with its expanded funding, the company is well-positioned to capitalize on market opportunities and drive innovation in the biotech space.

Company Info

Headquarters
Seattle, WA
Founded
2020
Team Size
250-500
Last Round
$400M Series D(Oct 2025)

Investors (2)

A
Andreessen HorowitzLead
Venture Capital
Leading venture capital firm investing in technology companies
N
NEA
Venture Capital
Leading venture capital firm investing in technology companies

Topics

Venture Capital(907)Technology(815)Startup Funding(564)Series(543)Biotech

Share

Related Reports

Biotech
AusperBio

AusperBio Raises $73M Series B

Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials

David Chen
David Chen
Dec 30, 2025
0 min read•$73M Series B
Biotech
Orna Therapeutics

Orna Therapeutics Raises $251M Series B

Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases

Emma Rodriguez
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics

Forge Biologics Raises $120M Series C

Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines

Sarah Kim
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C

Turn your sales ideas into reality today

Start your 14-day Pro trial today. No credit card required.

Start building for free